FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
Read the full article on Fox News
Read Full Article →